Auditory Late Effects of Chemotherapy (original) (raw)

• Fausti SA, Schechter MA, Rappaport BZ, et al. Early detection of cisplatin ototoxicity. Selected case reports. Cancer. 1984;53:224 231.
  PubMed CAS Google Scholar
• Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649 655.
  PubMed Google Scholar
• Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol. 1990;8:1191 1198.
  PubMed CAS Google Scholar
• Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417 422.
  PubMed CAS Google Scholar
• Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445 2451.
  PubMed CAS Google Scholar
• Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927 931.
  PubMed CAS Google Scholar
• Blakley BW, Myers SF. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg. 1993;109:385 391.
  PubMed CAS Google Scholar
• Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295 300.
  PubMed CAS Google Scholar
• Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med Pediatr Oncol. 1996;27:26 31.
  PubMed CAS Google Scholar
• Montaguti M, Brandolini C, Ferri GG, et al.[Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention]. Acta Otorhinolaryngol Ital. 2002;22:14 18.
  PubMed CAS Google Scholar
• Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355 1362.
  PubMed CAS Google Scholar
• Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669 674.
  PubMed CAS Google Scholar
• Brown RL, Nuss RC, Patterson R, et al. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol. 1983;16:254 262.
  PubMed CAS Google Scholar
• Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985;56:1934 1939.
  PubMed CAS Google Scholar
• Aguilar-Markulis NV, Beckley S, Priore R, et al. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. 1981;16:111 123.
  PubMed CAS Google Scholar
• Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol. 2007;71:1631 1638.
  Google Scholar
• Cohen BH, Zweidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg. 1990;16:292 296.
  PubMed Google Scholar
• Freilich RJ, Kraus DH, Budnick AS, et al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26:95 100.
  PubMed CAS Google Scholar
• Miettinen S, Laurikainen E, Johansson R, et al. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl. 1997;529:90 94.
  PubMed CAS Google Scholar
• Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754 760.
  PubMed CAS Google Scholar
• Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002;214:149 152.
  PubMed CAS Google Scholar
• Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985;12 Suppl A:125 136.
  PubMed CAS Google Scholar
• Meyers FJ, Welborn J, Lewis JP, et al. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol. 1989;7:173 178.
  PubMed CAS Google Scholar
• Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children’s Cancer Group. Cancer. 1994;73:1297 1301.
  Google Scholar
• Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50:223 226.
  PubMed Google Scholar
• Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol. 2002;39:163 167.
  PubMed Google Scholar
• Kennedy IC, Fitzharris BM, Colls BM, et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol. 1990;26:232 234.
  PubMed CAS Google Scholar
• Allen JRL. Modern-period muddy sediments in the severn estuary (Southwestern UK) A pollutant-based model for dating and correlation. Sedimentary Geol. 1988;58:1.
  CAS Google Scholar
• Macdonald MR, Harrison RV, Wake M, et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1994;23:151 159.
  PubMed CAS Google Scholar
• Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493 500.
  PubMed CAS Google Scholar
• Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery. 1995;37:17 27; discussion -8.
  PubMed CAS Google Scholar
• Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut. 1990;61:320 321.
  PubMed CAS Google Scholar
• Aydogdu I, Ozturan O, Kuku I, et al. Bilateral transient hearing loss associated with vincristine therapy: case report. J Chemother. 2000;12:530 532.
  Google Scholar
• Riga M, Psarommatis I, Korres S, et al. Neurotoxicity of vincristine on the medial olivocochlear bundle. Int J Pediatr Otorhinolaryngol. 2007;71:63 69.
  PubMed CAS Google Scholar
• Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol. 1983;12:365 369.
  PubMed CAS Google Scholar
• Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol. 1985;242:1 6.
  PubMed CAS Google Scholar
• Komune S, Asakuma S, Snow JB, Jr. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg. 1981;89:275 282.
  PubMed CAS Google Scholar
• Hoistad DL, Ondrey FG, Mutlu C, et al. Histopathology of human temporal bone after cis-platinum, radiation, or both. Otolaryngol Head Neck Surg. 1998;118:825 832.
  PubMed CAS Google Scholar
• Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995;16:731 740.
  PubMed CAS Google Scholar
• Dehne N, Lautermann J, Petrat F, et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol. 2001;174:27 34.
  PubMed CAS Google Scholar
• Takeno S, Harrison RV, Ibrahim D, et al. Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res. 1994;75:93 102.
  PubMed CAS Google Scholar
• Kwong DL, Wei WI, Sham JS, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys.1996;36:281 289.
  PubMed CAS Google Scholar
• Walker DA, Pillow J, Waters KD, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17:48 52.
  PubMed CAS Google Scholar
• Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588 8596.
  PubMed Google Scholar
• Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002;52:599 605.
  Google Scholar
• Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:917 924.
  PubMed CAS Google Scholar
• McHaney VA TG, Hayes FA. Hearing loss in children receiving cisplatin chemotherapy. K Pediatr. 1983;83:314 317.
  Google Scholar
• Pasic TR, Dobie RA. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:985 991.
  PubMed CAS Google Scholar
• Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24:918 924.
  PubMed CAS Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748 1756.
  PubMed CAS Google Scholar
• Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823 1828.
  PubMed CAS Google Scholar
• Peng B BA, English MW, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994;14:2279 2283.
  Google Scholar
• Posner MR, Ferrari L, Belliveau JF, et al. A phase I trial of continuous infusion cisplatin. Cancer. 1987;59:15 18.
  PubMed CAS Google Scholar
• Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol. 2001;57:393 402.
  PubMed CAS Google Scholar
• Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci. 1999;884:15 18.
  PubMed CAS Google Scholar
• Dominici C, Petrucci F, Caroli S, et al. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989;7:100 107.
  PubMed CAS Google Scholar
• Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther. 1990;6:145 151.
  PubMed CAS Google Scholar
• Gupta AA, Capra M, Papaioannou V, et al. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol. 2006;28:91 94.
  PubMed CAS Google Scholar
• Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47:183 193.
  PubMed CAS Google Scholar
• Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708 714.
  PubMed CAS Google Scholar
• Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639 643.
  PubMed CAS Google Scholar
• Kohn S, Fradis M, Podoshin L, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1997;107:407 408.
  PubMed CAS Google Scholar
• Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355 360.
  PubMed CAS Google Scholar
• Hallmark RJ, Snyder JM, Jusenius K, et al. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur J Gynaecol Oncol. 1992;13:35 44.
  PubMed CAS Google Scholar
• Gaegcnti DL. Childhood. In: Finegold M, Beningtion J, eds. Pathology of Neoplasia in Children and Adults. Philadelphia: WB Saunders. 1986:282 312.
  Google Scholar
• Buhrer C, Weinel P, Sauter S, et al. Acute onset deafness in a 4 year-old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol. 1990;7:145 148.
  PubMed CAS Google Scholar
• Berg AL, Spitzer JB, Garvin JH, Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109:1806 1814.
  PubMed CAS Google Scholar
• Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer. 2004;40:2352 2354.
  PubMed Google Scholar
• Northern JL, Downs MP. Hearing in Children, ed. Baltimore, MD: Williams & Wilkins, 1991
  Google Scholar
• American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 2004;35(Suppl 12):11 19.
  Google Scholar
• Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998;19:339 354.
  PubMed CAS Google Scholar
• Schmidt CM, Bartholomäus E, Deuster D, et al. The Muenster classification of high frequency hearing loss following cisplatin chemotherapy. HNO 2007;55(4):299 306.
  Google Scholar
• Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59:47 57.
  PubMed CAS Google Scholar
• Littman TA, Magruder A, Strother DR. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol. 1998;9:257 262.
  PubMed CAS Google Scholar
• Smith LJ, inventor Smith, L J (SMIT-Individual), assignee. Educational kit used for teaching paleontology to child. US. 1999 August 24.
  Google Scholar
• Sockalingam R, Freeman S, Cherny TL, et al. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol. 2000;21:521 527.
  PubMed CAS Google Scholar
• Toral RM, Skurovitch-Bialik P, Collado-Corona MA, et al. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch Med Res. 2003;34:205 208.
  Google Scholar
• Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope. 1994;104:1130 1134.
  PubMed CAS Google Scholar
• Subramaniam M, Salvi RJ, Spongr VP, et al. Changes in distortion product otoacoustic emissions and outer hair cells following interrupted noise exposures. Hear Res. 1994;74:204 216.
  PubMed CAS Google Scholar
• Dhooge I, Dhooge C, Geukens S, et al. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol. 2006;45:337 343.
  PubMed Google Scholar
• Campbell KC, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003;14:157 168; quiz 70 71.
  PubMed Google Scholar
• Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place Resident Clinical Science Award. 1998. Otolaryngol Head Neck Surg. 1999;121:693 701.
  PubMed CAS Google Scholar
• Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190 1195.
  PubMed CAS Google Scholar
• A. B. Room acoustics and speech perception. http://wwwwrohansdsuedu/aboothro/files/RoomAcoustics/Roomacousticsandspeechperceptionpdf, 2002.
• Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg. 2004;130:556 562.
  PubMed Google Scholar
• Stelmachowicz PG, Pittman AL, Hoover BM, et al. Effect of stimulus bandwidth on the perception of /s/ in normal- and hearing-impaired children and adults. J Acoust Soc Am. 2001;110:2183 2190.
  PubMed CAS Google Scholar
• French NR, Steinberg J. Factors governing the intelligibility of speech sounds. J Acoust Soc Am. 1947;19:90 119.
  Google Scholar
• Katz J WT. Introduction to the Handicap of Hearing Impairment: Auditory Impairment Versus Hearing Handicap.San Diego, CA: Singular Publishing Group; 1982.
  Google Scholar
• Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 1988;48:3641 3647.
  PubMed CAS Google Scholar
• Schiller JH. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol. 1996;23:78 82.
  PubMed CAS Google Scholar
• Schuchter LM. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur J Cancer. 1996;32A Suppl 4:S40 S42.
  Google Scholar
• Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629 638.
  PubMed CAS Google Scholar
• Block KI GC. Commentary: the pharmacological antioxidant amifostine implications of recent research for integrative cancer care. Integrative Cancer Therapies. 2005;4:325 351.
  Google Scholar
• Hussain AE, Blakley BW, Nicolas M, et al. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol. 2003;32:294 297.
  PubMed Google Scholar
• Ekborn A, Hansson J, Ehrsson H, et al. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. 2004;114:1660 1667.
  PubMed CAS Google Scholar
• Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841 847.
  PubMed CAS Google Scholar
• Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996;23:2 17.
  PubMed CAS Google Scholar
• Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res. 1996;56:706 709.
  PubMed CAS Google Scholar
• Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther. 1998;286:77 84.
  PubMed CAS Google Scholar
• Abe R, Akiyoshi T, Tsuji H, et al. Protection of antiproliferative effect of cis-diamminedichloroplatinum (II) by sodium thiosulfate. Cancer Chemother Pharmacol. 1986;18:98 100.
  PubMed CAS Google Scholar
• Elferink F, van der Vijgh WJ, Klein I, et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986;32:641 645.
  PubMed CAS Google Scholar
• Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052 1058.
  PubMed CAS Google Scholar
• Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90 98.
  PubMed CAS Google Scholar
• Reser D, Rho M, Dewan D, et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology. 1999;20:731 748.
  PubMed CAS Google Scholar
• Korver KD, Rybak LP, Whitworth C, et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002;126:683 689.
  PubMed Google Scholar
• Campbell KC, Meech RP, Rybak LP, et al. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res. 1999;138:13 28.
  PubMed CAS Google Scholar
• Sequoia Ecosystem and Recreation Preserve Act of 1999. In. 106th Congress ed; 1999.
  Google Scholar
• Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25:33 40.
  PubMed Google Scholar
• Church MW, Kaltenbach JA, Blakley BW, et al. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86:195 203.
  PubMed CAS Google Scholar
• Kaltenbach JA, Church MW, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg. 1997;117:493 500.
  PubMed CAS Google Scholar
• Copeland BJ, Pillsbury HC, 3rd. Cochlear implantation for the treatment of deafness. Annu Rev Med. 2004;55:157 167.
  PubMed CAS Google Scholar
• Brock P, Pritchard J, Bellman S, Pinkerton CR. Ototoxicity of high-dose cisplatinum in children. Med Pediatr Oncol.1988;16:368 369.
  PubMed CAS Google Scholar
• Brock P, Bellman S, Pritchard J. Ototoxicity of cisplatinum Br J Cancer.1991;63:159 161.
  PubMed CAS Google Scholar
• Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children; a practical grading system. Med Pediatr Oncol.1991;19:295 300.
  PubMed CAS Google Scholar
• Brock P, Yeomans E, Bellman S, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer. 1992;66:Suppl XVIII:S36 S40.
  Google Scholar